A biotech with a neurology pipeline was approaching their first approval in North America (US and Canada) and planning to file with EMA in advance of launches in EU markets (Germany, France, Italy, Spain, UK).
The client engaged Qral to provide research-driven strategic recommendations for commercialization priorities and scaling in these new markets.
Qral recommended a research methodology synthesizing primary and secondary research. Analog companies were identified and shortlisted. Desk research and interviews were conducted with industry experts and client team members with relevant experience. The project delivered an in-depth analog company study, a recommended global commercial blueprint, and country-level dossiers on launch timing and sequence considerations.
Recommended establishing strong affiliates in core markets and partnering out secondary countries until financial sustainability is proven. A phased launch timeline and country-level dossiers across 27 potential markets prioritized Japan and Western Europe following initial North American and EU5 approvals. Client implemented the recommended launch phasing and is now approaching the EU and Japan launches.
